Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phoenicia BioScience PKC delta inhibitor
- Development stage
- Preclinical
- Lead developer
- Phoenicia BioSciences
- Modality
- Small Molecules
- Administration
- Intraduodenal, Intratracheal, Intraperitoneal, Oral, Buccal, Sublingual, Topical, Intravenous, Subcutaneous, Transcutaneous, Transdermal, Intramuscular, Intraarticular, Parenteral, Intra-arterial, Intradermal, Intraventricular, Intracranial, Intralesional, Intranasal, Rectal, Vaginal, Inhalation, Via Implanted Reservoir
01
Overview
Phoenicia BioScience is developing a small molecule inhibitor of Protein Kinase C delta (PKCδ) specifically designed to treat RAS-driven cancers. PKCδ is a member of the novel protein kinase C (nPKC) subfamily and has been identified as a critical mediator of survival and proliferation in cells transformed by RAS oncogenes, such as KRAS, NRAS, and HRAS. By inhibiting PKCδ, the therapy aims to disrupt the downstream signaling pathways that RAS-mutant tumor cells depend on for survival, potentially offering a targeted approach for cancers that are traditionally difficult to treat with standard therapies.
- Other names
- PKCδ inhibitorProtein Kinase C delta inhibitorPKCδ (Protein Kinase C delta) inhibitors
02
Targets
PRKCD (Protein kinase C delta)
Beyond the preview
Go deeper on Phoenicia BioScience PKC delta inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phoenicia BioScience PKC delta inhibitor.